Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Feb 19;14(8):1252–1259. doi: 10.1080/15384101.2015.1014149

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Author(s). Published with license by Taylor & Francis Group, LLC

© Shumei Kato, Maria Schwaederle, Gregory A Daniels, David Piccioni, Santosh Kesari, Lyudmila Bazhenova, Kelly Shimabukuro, Barbara A Parker, Paul Fanta, and Razelle Kurzrock

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 1. — Frequency of CDK-associated genetic aberrations in 347 patients with diverse malignancies. Of 347 patients with diverse malignancies, 23% (N = 79) had an aberration in either CDK4 (N = 13 [3.7% of 347 patients]), CDK6 (N = 8 [2.3%]), CDKN2A (N = 62 [17.9%]) and/or CDKN2B (N = 37 [10.7%]). All cases with CDKN2B aberrations (N = 37) also had aberrant CDKN2A (but the opposite was not true). One case of CDK4 amplification had a co-existing CDKN2A/B aberration. CDK6 amplification occasionally co-existed with CDKN2A/B aberration (N = 2) or a CDKN2A aberration (N = 1).